InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,112.43
(
0.95%
)
US TECH 100
17,328.40
(
1.48%
)
Dow Jones
38,592.08
(
0.96%
)
Brent Oil
83.42
(
-0.26%
)
Bitcoin
61,369.27
(
3.80%
)
Post# of 251696
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 56
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: DFRAI post# 119343

Wednesday, 05/04/2011 9:04:05 PM

Wednesday, May 04, 2011 9:04:05 PM

Post# of 251696
The small, incremental increases in survival provided by Provenge, docetaxel, abiraterone, and Jevtana have increased the median survival of a metatstatic, castrate resistant prostate cancer patient by over 78%.

It is the "incremental advancement" you wish to stop that has provided significant hope for cancer patients over the past three decades. We will never cure cancer, only make it into a chronic disease that doesn't much bother the patient.

And none of the companies you mention will provide anything other than one more incremental improvement in survival. But that's OK.

Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up